Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 12/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 5/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30774354 | 0.96 | USP30 (0.43) | PRKAA2USP30S1PR5DPP4DPP8 | |
| SCHEMBL30774590 | 0.90 | USP30 (0.42) | USP30CYP11B1CYP11B2 | |
| SCHEMBL30774349 | 0.89 | PRKAB2 (0.42) | PRKAA2USP30PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL30774840 | 0.87 | ROCK2 (0.44) | USP30DRD2DRD3 | |
| SCHEMBL30774432 | 0.87 | USP30 (0.42) | USP30CYP11B2 | |
| SCHEMBL30774559 | 0.85 | USP30 (0.41) | PRKAA2USP30PRKAB2PRKAG1PRKAA1 | |
| SCHEMBL30774644 | 0.85 | USP30 (0.46) | USP30 | |
| SCHEMBL30774398 | 0.85 | USP30 (0.46) | USP30 | |
| SCHEMBL30773967 | 0.84 | NAAA (0.40) | PRKAA2CYP11B1CYP11B2DRD2 | |
| SCHEMBL30774542 | 0.84 | USP30 (0.40) | PRKAA2USP30PRKAB2PRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | claimed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | claimed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024061371-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州威诺森医药科技有限公司 | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | PRKAA2 1880/4885USP30 728/4885PRKAB2 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.